UNSPSC 51161536: Doxofylline

This classification denotes a phosphodiesterase inhibitor with the molecular formula C11H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MPM23GMO7Z, chemically known as 7-(1,3-dioxolon-2-ylmethyl)-1,2,3,6-tetrahydro-1,3-dimethyl-2,6-purindion but generally known as doxofylline, which bears US NIH Compound Identifier 50942. European Medicines Agency schedules Doxofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06390MIG. The term DOXOFYLLINE is an International Non-Proprietary Name.

UNSPSC 51161536 Doxofylline, a Commodity code, represents pharmaceutical active ingredients and finished products that state and local health systems and correctional facilities procure through cooperative purchasing agreements and direct solicitations. The code encompasses prescription and over-the-counter medications supplied by pharmaceutical manufacturers to government health agencies, public hospitals, correctional departments, and other state entities. Recent activity shows state health authorities and multistate cooperative purchasing alliances buying generic pharmaceuticals and OTC products from manufacturers in bulk, with awards contingent on cGMP certification, FDA compliance, established relationships with authorized pharmaceutical wholesalers, and demonstrated pricing flexibility across multiple net-price and WAC-minus structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating Minnesota and Oregon government facilities. The RFP requires manufacturers to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), submit comprehensive product information including NDC codes and packaging configurations, maintain contractual relationships with at least two of the three wholesalers, and provide pricing in flat-price, net-price, or WAC-minus formats. The proposal deadline was March 26, 2026, with awarded vendors to be provided to wholesalers by May 15, 2026 and contract effectiveness July 1, 2026. Evaluation weights pricing competitiveness at 75 percent, fixed pricing at 10 percent, and administrative compliance (EDI capability, fee-format certification, and compliance documentation) at the remaining 15 percent. The RFP imposed no disclosed set-aside restrictions and required vendors to carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability coverage. The contract term runs two years for new respondents with optional MMCAP extensions, while incumbent vendors' amendments align with existing expiration dates through June 30, 2028.